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Abstract 
Purpose: To describe ICU stay, selected management aspects, and outcome of Intensive Care Unit (ICU) patients 
with traumatic brain injury (TBI) in Europe, and to quantify variation across centers.
Methods: This is a prospective observational multicenter study conducted across 18 countries in Europe and Israel. 
Admission characteristics, clinical data, and outcome were described at patient- and center levels. Between-center 
variation in the total ICU population was quantified with the median odds ratio (MOR), with correction for case-mix 
and random variation between centers.
Results: A total of 2138 patients were admitted to the ICU, with median age of 49 years; 36% of which were mild 
TBI (Glasgow Coma Scale; GCS 13–15). Within, 72 h 636 (30%) were discharged and 128 (6%) died. Early deaths and 
long-stay patients (> 72 h) had more severe injuries based on the GCS and neuroimaging characteristics, compared 
with short-stay patients. Long-stay patients received more monitoring and were treated at higher intensity, and 
experienced worse 6-month outcome compared to short-stay patients. Between-center variations were prominent in 
the proportion of short-stay patients (MOR = 2.3, p < 0.001), use of intracranial pressure (ICP) monitoring (MOR = 2.5, 
p < 0.001) and aggressive treatments (MOR = 2.9, p < 0.001); and smaller in 6-month outcome (MOR = 1.2, p = 0.01).
Conclusions: Half of contemporary TBI patients at the ICU have mild to moderate head injury. Substantial between-
center variations exist in ICU stay and treatment policies, and less so in outcome. It remains unclear whether admis-
sion of short-stay patients represents appropriate prudence or inappropriate use of clinical resources.
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Introduction
Traumatic brain injury (TBI) causes a social and 
economic global burden with about 82,000 deaths 
in Europe every year [1]. Patients with severe TBI 
often receive a highly intensive and multidisciplinary 
approach to prevent or mitigate both secondary brain 
injury and systemic complications [2]. For less severe 
TBI cases (without severe extracranial injury), clini-
cians have to estimate whether they will benefit from 
ICU admission, since guidelines with high-level evi-
dence on ICU admission criteria are lacking. ICU 
admission is costly, and might also potentially be inap-
propriate for the patient, with risk of overtreatment 
and ICU-related complications, such as infections from 
multi-resistant bacteria [3].
In previous studies, intensive care admission was 
described merely for the most severe TBI cases, typically 
young male victims of high-energy road traffic incidents. 
In high-income countries, however, the aging popula-
tion and the reduction of road traffic incidents have led 
to important changes in TBI epidemiology, which now 
includes older patients, who are often victims of falls, 
and present with frequent co-morbidities but less severe 
brain injury. Recent data suggest that the landscape of 
TBI in Europe is changing and that, correspondingly, 
ICU admission policies may have been modified, includ-
ing a larger proportion of milder TBI patients [4, 5].
The aims of this study were:
1. to provide a general description of ICU stay, selected 
management aspects and outcome in TBI patients 
across Europe and,
2. to quantify variation across centers.
Methods
CENTER‑TBI study
The Collaborative European NeuroTrauma Effectiveness 
Research in Traumatic Brain Injury (CENTER-TBI study, 
registered at clinicaltrials.gov NCT02210221), entails a 
longitudinal prospective collection of TBI patient data 
across 63 centers in Europe and Israel between December 
19, 2014 and December 17, 2017. Inclusion criteria were: 
(1) clinical diagnosis of TBI; (2) indication for a brain 
CT scan; and (3) presentation to the hospital within 24 h 
post-injury. The presence of a severe preexisting neuro-
logical disorder, potentially confounding outcome assess-
ment, was the only exclusion criterion. The CENTER-TBI 
study was approved by the medical ethics committees of 
all participating centers and informed consent from the 
patient or legal representative was obtained according to 
local regulations [4, 6].
ICU population and data collection
All patients directly admitted from the Emergency Room 
or transferred within 24 h of injury from another hospital 
to the ICU were analyzed [4]. Patients who deteriorated 
at the trauma, neurological or neurosurgical ward and 
were (re)admitted to the ICU were not included. Clinical 
data were collected at ICU admission, during ICU stay 
and at ICU discharge. For the current study, we extracted 
data on demographics, injury, imaging, admission, moni-
toring, treatment, and outcome characteristics. Patients 
were stratified using baseline GCS scores as mild (GCS 
13–15), moderate (GCS 9–12), or severe TBI (GCS < 9) 
[4].
ICP and ICP‑lowering treatments
Intracranial pressure and cerebral perfusion pres-
sure (CPP) values were collected every 2  h. Intracranial 
hypertension was defined as a value above 20  mmHg, 
while 60  mmHg was chosen as a threshold for low 
CPP. To quantify the intensity of ICP-targeted thera-
pies, a recently updated and validated version of the 
therapy intensity level (TIL) scale was used [7]. This 
scale summarizes in a score the number and the inten-
sity of treatments. In addition, we analyzed the use of 
aggressive treatments for raised ICP as hypothermia, 
intense hypocapnia, barbiturates and decompressive 
craniectomy.
Outcome
Outcome was measured at 6  months after injury using 
the Glasgow Outcome Scale-Extended (GOSE), adminis-
tered by interview or postal questionnaire. The categories 
‘vegetative state (GOSE 2)’ and ‘lower severe disability 
(GOSE 3)’ were combined, resulting in a seven-point 
ordinal scale.
Statistical analysis
Patient characteristics are described as mean and stand-
ard deviation (SD) or as median and interquartile range 
(IQR). We defined three groups: early deaths (died 
within ≤ 72 h of ICU admission), short stay (≤ 72 h in the 
ICU) and long stay (> 72 h in the ICU). Patient character-
istics, treatments and outcome were compared between 
these groups with χ2 tests for categorical variables, and 
Take‑home message 
Patients with traumatic brain injury admitted to intensive care units 
are older and often less severe than in previous studies. Substantial 
between-center variation exists in ICU admission and treatment 
policies across Europe.
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ANOVA and t tests for continuous variables. We used 
the IMPACT Core model to calculate expected mortal-
ity and proportion with unfavorable outcome (GOSE < 5).
The variation between centers was quantified using 
random-effect logistic and ordinal regression models 
with a random intercept for center, and expressed as the 
median odds ratio [8] for:
1. The proportion of patients with a short stay (≤ 72 h 
in the ICU) versus long stay (> 72 h) and early deaths 
(≤ 72 h).
2. The proportion of cases having received ICP moni-
toring. Also, a sensitivity analysis of the proportion 
of cases having received ICP monitoring in a subset 
of patients with a GCS < 8 and CT abnormalities was 
performed.
3. The use of aggressive ICP-lowering treatments (any 
use of decompressive craniectomy, metabolic sup-
pression, hypothermia therapy or intensive hypocap-
nia).
4. 6-month GOSE outcome.
The MOR is a measure of variation in treatments or 
outcomes between hospitals that is not explained by fac-
tors in the model or attributable to chance. The MOR is 
related to τ2, which is the variance of the random effects:
The MOR can be interpreted as the odds ratio for com-
paring two randomly selected centers. For example, a 
MOR equal to one indicates no differences between cent-
ers. If there is considerable between-center variation, the 
MOR will be large. For example, a MOR of 2 for a certain 
treatment indicates that if two TBI patients with the same 
injury severity and characteristics presented to two ran-
dom centers in our sample, one patient will have an over 
twofold probability to receive that treatment. To adjust 
for differences in baseline risk, we included the variables 
from the International Mission for Prognosis and Analy-
sis of Clinical Trials in TBI (IMPACT) lab prognostic 
model [9] and any major extracranial injury [defined as 
an Abbreviated Injury Scale (AIS) > 3] [10]. The likeli-
hood ratio test was used to determine the significance of 
the between-center variation, comparing a model with 
and without a random effect for center. The correspond-
ing p values require a mixture distribution since the null 
hypothesis is on the boundary of the parameter space) 
[11].
Statistical analyses were performed in the R statisti-
cal software [12]. Multipleimputation was used to han-
dle missing values, with use of the mice package in R 
[13]. These analyses were based on Version 2.0 of the 
MOR = exp
[√
2× τ 2 × 0.6745
]
≈ exp (0.95τ).
CENTER-TBI core dataset, accessed using a bespoke 
data management tool, ‘Neurobot’ (http://neuro bot.incf.
org; RRID: SCR_01700).
Results
Patient characteristics
A total of 4509 patients were enrolled in the CENTER-
TBI study, 2138 of whom were admitted to the ICU and 
included in this study. Patients were mostly men (73%). 
The median age was 49  years (IQR 29–65). A minority 
were children younger than 18 years (132, 6%), 552 (26%) 
were older than 65 years and 94 (4%) older than 80 years. 
Patients with severe TBI constituted 48% of the ICU 
admissions, while 720 cases (36%) were classified as mild. 
Major extra-cranial injuries were present in 1174 (55%) 
patients. (Table  1). More than half of the 54 ICUs have 
a neuro-ICU available (35, 65%). The median number of 
ICU beds available was 35 (28–45). Thirty-eight ICUs 
had a step-down unit available (70%). (Table  S1) The 
median number of ICU patients recruited was 28 with an 
IQR of 15–50 (range 1–140). The median length of stay 
for the entire ICU cohort was 11 (IQR 3–26) days.
ICU mortality and discharge rates were high in the first 
72 h, but declined over time (Figs. 1, 2). There were 128 
(6%) early deaths, 636 (30%) short-stay, and 1372 (64%) 
long-stay cases (Fig. 2).
Early death patients had a higher median age (62 years) 
and more severe injuries, both intracranial and extracra-
nial, compared to survivors. Demographic features were 
comparable between short-stay and long-stay groups, 
while significant differences were identified with respect 
to injury severity, CT findings, and pre-admission insults 
(Table  1). The main cause of mortality in early death 
patients was due to initial head injury (78, 81%) (Fig. S2).
The most frequent reasons for admission in short-stay 
patients were the need for frequent neurological obser-
vations (340; 54%) and mechanical ventilation (154; 24%) 
(Fig. S3). The long-stay patients included 319 patients 
(25%) classified as mild TBI in whom similar reasons 
for admission were mentioned (the need for neurologi-
cal observations (152, 48%), mechanical ventilation (96, 
30%).
Monitoring and treatment
Mechanical ventilation for at least 24  h was most often 
applied in long-stay patients and in patients who died 
early, when compared to short-stay patients (1164 [85%] 
and 91 [71%]; versus 201 [32%], respectively). A large dif-
ference was found in the use of ICP monitoring between 
long-stay and short-stay cases (837; 62% versus: 41; 7%, 
respectively). The main indication for ICP monitoring 
in short-stay patients was surveillance after intracranial 
operation (31, 76%). Invasive blood pressure monitoring 
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was used in the majority of long-stay patients (1227; 90%) 
and in early deaths (113; 89%); but less frequently (388; 
62%) in short-stay patients (Table S2).
Both neurosurgical interventions and extracranial sur-
gery were more common in long-stay patients (634; 47% 
and 467; 34%, respectively) when compared to short-stay 
patients (139; 22% and 122; 19%, respectively). Patients 
in the short stay group rarely (≤ 5%) received aggressive 
ICP treatments (i.e., decompressive craniectomy, meta-
bolic suppression, hypothermia, or intensive hypocapnia) 
(Table S2).
Complications and outcome
Long-stay patients suffered more complications com-
pared with short-stay patients: most commonly ventilator 
acquired pneumonia (276; 21% versus 3; 0.5%) and car-
diovascular complications (125; 9.3% versus 9; 1.5). The 
overall median hospital length of stay was 11 days (IQR: 
3.4–26), while the median hospital length of stay for 
long-stay patients was 18 days (IQR: 7.7–35). When com-
pared to long-stay patients, short-stay patients were less 
oftendischarged to a step-down unit (86 [14%] vs 255 
[21%], respectively), and more often transferred to the 
ward (486 [78%] versus 616 [51%]). Long-stay patients 
were also often discharged to other hospitals (174; 14%) 
and rehabilitation units (95; 8%); while, other discharge 
locations (such as home, other ICU, or nursing home) 
were rare (Table 2).
In-hospital mortality for the ICU stratum was 15%; 
and at 6 months, mortality rose to 21% (data available for 
Table 1 Baseline characteristics
This table shows the baseline characteristics for short stay (stay ≤ 72 h), long stay (stay > 72 h), and early deaths (≤ 72 h). p values from ANOVA and Chi-square statistics 
for continuous and categorical characteristics, respectively
AIS Abbreviated Injury Scale, tSAH traumatic subarachnoid hemorrhage
Total
2138
Short stay
636
Long stay
1372
Early deaths
128
p value
Age (median (IQR)) 49 (29–65) 48 (28–64) 49 (29–64) 62 (40–75) < 0.001
 ≥ 65 years 552/2138 (26%) 153/636 (24%) 337/1372 (25%) 62/128 (48%) < 0.001
 ≥ 80 years 94/2138(4.4%) 29/636 (4.6%) 52/1372 (3.8%) 13/128 (10%) 0.003
Male sex 1562/2138 (73%) 443/636 (70%) 1023/1372 (75%) 94/128 (73%) 0.07
Severity TBI < 0.001
 Mild 720/2009 (36%) 394/607 (65%) 319/1285 (25%) 6/116 (5.2%)
 Moderate 328/2009 (16%) 107/607 (18%) 213/1285 (17%) 8/116 (6.9%)
 Severe 961/2009 (48%) 106/607 (18%) 753/1285 (59%) 102/116 (88%)
Pupillary reactivity < 0.001
 Both reacting 1636/2016 (81%) 564/606 (93%) 1040/1287 (81%) 31/122 (25%)
 Both unreacting 246/2016 (12%) 16/606 (2.6%) 150/1287 (12%) 80/122 (65%)
 One reacting 134/2016 (6.6%) 26/606 (4.3%) 97/1287 (7.5%) 11/122 (9%)
Hypoxia 266/1981 (13%) 38/593 (6.4%) 191/1266 (15%) 37/121 (31%) < 0.001
Hypotension 267/1992 (13%) 36/595 (6.1%) 189/1274 (15%) 42/122 (34%) < 0.001
ISS [median (IQR)] 29 (25–41) 24 (16–29) 34 (25–43) 58 (28–75) < 0.001
Any major extracranial injury (AIS ≥ 3) 1174/2138 (55%) 283/636 (45%) 823/1372 (60%) 67/128 (53%) < 0.001
CT characteristics
 Marshall CT classification < 0.001
  I 204/1854 (11%) 110/566 (19%) 90/1179 (7.6%) 3/108 (2.8%)
  II 889/1854 (48%) 330/566 (58%) 553/1179 (47%) 6/108 (5.6%)
  III 152/1854 (8.2%) 19/566 (3.4%) 105/1179 (8.9%) 28/108 (26%)
  IV 28/1854 (1.5%) 4/566 (0.7%) 17/1179 (1.4%) 7/108 (6.5%)
  V/VI 581/1854 (31%) 103/566 (18%) 414/1179 (35%) 64/108 (59%)
 Epidural hematoma 369/1854 (20%) 120/566 (21%) 234/1179 (20%) 15/108 (14%) 0.22
 tSAH 1347/1854 (73%) 318/566 (56%) 930/1179 (79%) 99/108 (92%) < 0.001
 Contusion 1032/1854 (56%) 244/566 (43%) 730/1179 (62%) 58/108 (54%) < 0.001
 Acute subdural hematoma 911/1854 (49%) 192/566 (34%) 633/1179 (54%) 86/108 (80%) < 0.001
 Midline shift 404/1854 (22%) 77/566 (14%) 281/1179 (24%) 54/108 (50%) < 0.001
 Basal cistern absent or compressed 586/1854 (32%) 81/566 (14%) 415/1179 (35%) 94/108 (87%) < 0.001
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p < 0.001, Fig.  4). A sensitivity analysis (with a subset of 
patient with a GCS ≤ 8 and CT abnormalities) confirmed 
this between-center variation (MOR: 2.6, p < 0.001). After 
case-mix adjustment, significant between-center differ-
ences were also found in the use of aggressive therapies 
(MOR: 2.9, p < 0.001, Fig. 4).
Between-center variation in outcome was smaller com-
pared to the variation in treatment. The MOR in the total 
ICU population for six-month GOSE was 1.2 (p = 0.01, 
Fig. 4).
Discussion
The aims of this study were to describe ICU admission 
policies, selected management aspects, and outcome in 
TBI patients across Europe both at the patient and center 
levels. A substantial proportion of patients admitted to 
the ICU were classified on presentation as having a mild 
or moderate TBI. This is in strong contrast with historical 
TBI series, such as the USA Traumatic Coma Data Bank 
study [14] and other studies [15]. However, those series 
included only severe TBI patients, so that any evaluation 
of the general ICU admission policies at that time for 
milder cases is impossible. A more recent study, which 
analyzed data from 1648 mild TBI patients in 11 US level 
I trauma centers, showed that about 24 percent of them 
required admission to the ICU at some stage [16].
Fig. 1 ICU patient flow over time. a Plot of the dynamic states of 
patients with TBI that were admitted to the ICU during the first seven 
days after ICU admission. The y-axis represents the probability to be in 
one of the possible states (i.e., alive or dead or discharged from ICU) at 
each time point from ICU admission. *Died after ICU discharge. b Plot 
of the dynamic states of patients with TBI that were admitted to the 
ICU during the first 6 months after ICU admission. The y-axis represents 
the probability to be in one of the possible states (i.e., alive or dead or 
discharged from ICU) at each point from ICU admission. *Still in ICU
Fig. 2 Flowchart of ICU patients. This figure shows the flow of 
patients at the ICU, based on their length of stay. *Patients who died 
within 72 h at the ICU
1846 cases), which was lower than the expected mortality 
based on the IMPACT model (30%). Six-month mortality 
was higher in the long-stay-patient group compared with 
the short-stay group (20% versus 5.5%) (Fig. 3, Table 2).
An unfavorable outcome at 6  months (GOSE < 5) was 
observed in 43% in the total ICU stratum, 50% (590) in 
long-stay group, and in 15% in short-stay group (77). The 
unfavorable outcome rate in the total ICU stratum was 
similar to the expected rate based on the IMPACT model 
(49%).
Between‑center differences
Substantial between-center differences were found in 
the proportion of short stay, long stay and early deaths 
(MOR: 2.3, p < 0.001, Fig. 4). When adjusted for case-mix 
and random variation, between-center variation in the 
proportions of patients in the short-stay versus long-stay 
and early death groups was still substantial (MOR: 2.3, 
p < 0.001).
Regarding ICP monitoring, after adjustment for case-
mix, substantial and significant between-center varia-
tion persisted in the use of ICP monitoring (MOR: 2.5, 
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Even when compared to these latter data, our findings 
indicate quite liberal ICU admission rates for less severe 
cases. This is consistent with the strategies declared by 
the majority of centers participating in CENTER TBI. 
When centers were asked (in the Provider Profiling sur-
vey; see [5]) if they would admit “patients with a Glas-
gow Come Score (GCS) between 13 and 15 without 
CT abnormalities but with other risk factors”, 68% of 
responders reported this as consistent with their center 
policy.
Among the cases admitted, we looked at three differ-
ent patient groups. Around 6% of patients died in the 
first 3 days after admission, with clearly severe intracra-
nial and extra-cranial injuries. Patients in this group were 
significantly older, and only approximately half of those 
with documented intracranial mass lesions in this group 
received an operation. In survivors, we studied two dis-
tinct groups: those with a brief transition through the 
ICU and the second characterized by a prolonged ICU 
treatment. We selected the first 72 h as criterion to sepa-
rate these two patient streams, triggered by the high ICU 
discharge rate during the first 3  days. This separation 
identified patients with different clinical characteristics, 
care pathways, and outcomes: long-stay patients were 
more severely injured, required more frequent invasive 
monitoring (including ICP) and therapies (both surgical 
and medical), and suffered a worse outcome. In contrast, 
short-stay patients were less severely injured, received 
less monitoring and treatments, and achieved better out-
comes. The most frequently indicated reasons for ICU 
admission in this latter group were the need for strict 
neurological observation and mechanical ventilation 
(which, however, was continued for at least 24 h only in 
Table 2 Outcome and complications
This table shows the outcomes and ICU complications for patients surviving more than 72 h after ICU admission. The data are shown for short-stay (stay ≤ 72 h) or 
long-stay (stay > 72 h) patients. Early deaths are not included in this table as these patients represent the outcome in itself (death) and follow-up cannot be described. 
The categories ‘vegetative state (GOSE 2)’ and ‘lower severe disability (GOSE 3)’ were combined resulting in a seven-point ordinal scale’. p values from ANOVA and Chi-
square statistics for continuous and categorical characteristics, respectively
GOSE Glasgow outcome scale extended, ICU intensive care unit, IQR interquartile range
Total
2138
Short stay
636
Long stay
1372
p value
Outcomes
 6-month mortality 394/1846 (21%) 29/531 (5.5%) 237/1187 (20%) < 0.001
 6-month unfavorable outcome (GOSE < 5) 795/1846 (43%) 77/531 (15%) 590/1187 (50%) < 0.001
 Hospital length of stay in days (median (IQR)) 11 (3.4–26) 6.3 (3–11) 18 (7.7–35) < 0.001
 Discharge location from ICU < 0.001
  General ward 1102/1840 (60%) 486/623 (78%) 616/1216 (51%)
  Home 15/1840 (0.8%) 11/623 (1.8%) 4/1216 (0.3%)
  Nursing home 4/1840 (0.2%) 2/623 (0.3%) 2/1216 (0.2%)
  Other 36/1840 (2%) 5/623 (0.8%) 30/1216 (2.4%)
  Other hospital 201/1840 (11%) 27/623 (4.3%) 174/1216 (14%)
  Other ICU 43/1840 (2.3%) 3/623 (0.5%) 40/1216 (3.3%)
  Rehab unit 98/1840 (5.3%) 3/623 (0.5%) 95/1216 (7.8%)
  Step-down/high-care unit 341/1840 (19%) 86/623 (13.8%) 255/1216 (21%)
Complications at the ICU
 Ventilator acquired pneumonia 280/2090 (13%) 3/616 (0.5%) 276/1347 (21%) < 0.001
 Cardiovascular complications 155/2091 (7.4%) 9/616 (1.5%) 125/1348 (9.3%) < 0.001
 Meningitis 49/2090 (2.3%) 0/616 (0%) 48/1347 (3.6%) < 0.001
 Seizures 121/2089 (5.8%) 17/616 (2.8%) 99/1346 (7.4%) < 0.001
Fig. 3 Six-month Glasgow outcome scale extended. This figure 
shows the distribution of the functional outcomes at the GOSE 
after 6 months for all ICU patients, short-stay patients, and long-stay 
patients
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a third of cases). This may reflect current policy of early 
intubation at the scene of accident, and/or during ini-
tial assessment and evaluation. Cranial and extra-cranial 
surgery could also have been alternative indications for a 
short period of intense post-operative observation in the 
ICU.
These data can be interpreted in one of the two ways. 
On the one hand, the observed practice may repre-
sent a prudent strategy, offering close surveillance and 
assistance to patients at relatively low risk, but with the 
opportunity to ensure consistently good outcomes. The 
risk of deterioration in mild TBI is low but non-negli-
gible. A recent meta-analysis, including 45 studies (for 
a total of 65,724 patients), estimated a 12% incidence 
of neurological deterioration and 3.5% neurosurgical 
intervention in mild TBI (characterized as GCS 13–15) 
[17]. Alternatively, the observed admission strategies 
may represent costly over-triage, because the ICU is 
an expensive resource, which should be used wisely. 
The fact that 11 patients in the short-stay group were 
discharged home directly from the ICU raises strong 
reservations on their need for intensive care. A previ-
ous study in mild TBI patients in the ICU in the USA 
showed that 17% of cases were over-triaged, with over 
triaged patients defined as “ICU stay ≤ 1  day; hospital 
stay ≤ 2 days; no intubation; no neurosurgery; and dis-
charged to home” [18]. Our data on ICU admission of 
mild TBI patients are partially concordant with these 
findings, and while they do not permit accurate cost–
benefit analysis, they clearly indicate a trend in ICU 
admission policies that deserves attention.
After adjustment for case-mix and random variation 
between centers, we found significant between-center 
proportion of short-stay patients discharged alive within 
72  h. This confirms the results of earlier studies that 
found large variation in admission and discharge poli-
cies, primarily for mild TBI patients [5, 18]. This variation 
might reflect various factors: a search towards more indi-
vidualized management [2], a lower adherence to guide-
lines [19], different availability of resources, or various 
Fig. 4 Between-center differences in ICU policies and outcome. This panel shows the adjusted differences (adjusted for case-mix with the IMPACT 
prognostic model) between centers by considering. a The proportion of patients with a short stay (≤ 72 h in the ICU) versus long stay (> 72 h) and 
early deaths (≤ 72 h); long stay and early deaths were treated as one group, since they resemble more severe patients and we aimed to study the 
proportion in each center of short-stay patients that were discharged alive within 72 h. b GOSE at 6 months for total ICU population. c ICP monitor-
ing. d Aggressive therapy (any use of decompressive craniectomy, metabolic suppression, hypothermia therapy or intensive hypocapnia during ICU 
stay). A random-effect regression model was used to correct for random variation and adjusted for case-mix severity using the IMPACT variables and 
the presence of any major extracranial injury. The MOR reflects the between-center variation; a MOR equal to 1 represents no variation, the larger 
the MOR, the larger the variation. Significant differences (p value < 0.001) are present for data shown in a, c, and d for b (p = 0.01). GOSE Glasgow 
Outcome Scale extended, ICP intracranial pressure, MOR median odds ratio
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combinations of these different factors. As for monitor-
ing and management variations among centers, heteroge-
neity was not unexpected: previous studies [19–21] and 
surveys [22–24] found profound dissimilarities between 
centers in monitoring and treatment policies similar to 
our study.
The MOR for outcome between centers (1.2) was sig-
nificant (p = 0.01), but smaller than the MOR for case-
mix, ICP monitoring and aggressive therapies (2.5–2.9). 
This may reflect the small proportion of outcome vari-
ance modifiable by differences in management, and/or 
that differences in individual aspects of management may 
be discordant and make any outcome impact less easily 
detectable. Further, between-center variations in out-
come that we demonstrated were smaller than previously 
reported [25, 26]. This may be because previous analyses 
were based on older data, collected across multiple stud-
ies, and heterogeneity in time and location explained the 
larger outcome variance in these older reports. It is also 
possible that over time, a more homogeneous standard of 
treatment has evolved in Europe and Israel.
Strengths and limitations
The CENTER-TBI study is unique for its extensive data 
collection inmultiple centers, enrolling TBI patients with 
varying injury severity across a wide range of European 
centers. Limitations include that we focused on the ICU 
while an individual patient’s fate, and policies of the 
center at which treatment is delivered, depends on the 
continuum of care (from pre-hospital to rehabilitation). 
Second, the centers differed in their ICU characteristics, 
which might potentially contribute to between-center 
differences in ICU stay, treatment and outcome. In addi-
tion, we might have missed some important case-mix 
variables in the models that might have contributed to 
differences between centers (instead of true differences 
in policies). Third, the low number and non-consecutive 
enrolment in some centers could result in non-represent-
ative recruitment with reference to local ICU admission 
policy and introduce selection bias. Finally, all centers 
participating in CENTER TBI are characterized by their 
commitment to TBI research. They might represent a 
selected sample of the neuro-trauma centers in Europe 
limiting generalizability.
Future directions
The observed between-center differences in ICU poli-
cies require further research on whether these differ-
ences impact patient outcome. Comparative effectiveness 
research (CER) can be used for this purpose [27], requir-
ing adequate covariate adjustment to account for con-
founders, and adjustment for other treatment policies 
that might differ between the centers. Variation in ICU 
performance also provides opportunities for future 
benchmarking and quality initiatives.
Conclusions
Our results confirm that the current ICU patient popu-
lation admitted with Traumatic Brain Injury across 
Europe has changed, compared to previous data, and 
now includes older patients and a substantial proportion 
of mild and moderate cases. Sub-populations of patients 
(which we defined as short-stay, long-stay, and early 
mortality groups), are clearly different in injury severi-
ties, indications for ICU admission, care pathways, ICU 
resource utilization, and outcome. Our per-center analy-
sis identified differences in the proportion of short-stay 
patients and interventions, for instance in the use of ICP 
monitoring and aggressive therapy, while there were only 
small differences in outcome.
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